<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Epidemiology and pathogenesis of acute pulmonary embolism in adults</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Epidemiology and pathogenesis of acute pulmonary embolism in adults</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Epidemiology and pathogenesis of acute pulmonary embolism in adults</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">B Taylor Thompson, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Christopher Kabrhel, MD, MPH</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jess Mandel, MD, MACP, ATSF, FRCP</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Geraldine Finlay, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 04, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Acute pulmonary embolism (PE) is a form of venous thromboembolism (VTE) that is common and sometimes fatal. The clinical presentation of PE is variable and often nonspecific making the diagnosis challenging. The evaluation of patients with suspected PE should be efficient so that patients can be diagnosed and therapy administered quickly to reduce the associated morbidity and mortality.</p><p>The definition, epidemiology, pathogenesis, and pathophysiology of PE are discussed in detail in this topic. A detailed discussion of the diagnosis and treatment of PE is provided separately. (See  <a class="medical medical_review" href="/d/html/8261.html" rel="external">"Clinical presentation, evaluation, and diagnosis of the nonpregnant adult with suspected acute pulmonary embolism"</a> and  <a class="medical medical_review" href="/d/html/8265.html" rel="external">"Treatment, prognosis, and follow-up of acute pulmonary embolism in adults"</a>.) <span class="utd-adt-cnt utd-adt-pathwys utd-content-120066 utd-content-120062 utd-content-120060 utd-content-120061">(Related Pathway(s):  <a class="utd-content-120066" href="/pathway/120066?topicRef=8253&amp;source=see_link">Pulmonary embolism: Diagnostic evaluation in adults who are hemodynamically stable</a> and  <a class="utd-content-120062" href="/pathway/120062?topicRef=8253&amp;source=see_link">Pulmonary embolism: Diagnostic evaluation in adults who are hemodynamically unstable despite resuscitative efforts</a> and  <a class="utd-content-120060" href="/pathway/120060?topicRef=8253&amp;source=see_link">Pulmonary embolism (confirmed or suspected): Initial management of hemodynamically stable adults</a> and  <a class="utd-content-120061" href="/pathway/120061?topicRef=8253&amp;source=see_link">Pulmonary embolism (confirmed or suspected): Initial management of hemodynamically unstable adults</a>.)</span></p><p class="headingAnchor" id="H2"><span class="h1">DEFINITION AND NOMENCLATURE</span></p><p class="headingAnchor" id="H86227294"><span class="h2">Definition</span><span class="headingEndMark"> — </span>Pulmonary embolus (PE) refers to obstruction of the pulmonary artery or one of its branches by material (eg, thrombus, tumor, air, or fat) that originated elsewhere in the body. This topic review focuses upon PE due to thrombus. Tumor, air, and fat emboli are discussed separately. (See  <a class="medical medical_review" href="/d/html/8252.html" rel="external">"Pulmonary tumor embolism and lymphangitic carcinomatosis in adults: Diagnostic evaluation and management"</a> and  <a class="medical medical_review" href="/d/html/8263.html" rel="external">"Air embolism"</a> and  <a class="medical medical_review" href="/d/html/1602.html" rel="external">"Fat embolism syndrome"</a>.)</p><p class="headingAnchor" id="H86227300"><span class="h2">Nomenclature</span><span class="headingEndMark"> — </span>PE can be classified by the following:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>The temporal pattern of presentation (acute, subacute, or chronic)</strong> – Patients with PE can present acutely, subacutely, or chronically:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Acute – Patients with acute PE typically develop symptoms and signs immediately after obstruction of pulmonary vessels.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Subacute – Some patients with PE may also present subacutely within days or weeks following the initial event.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Chronic – Patients with chronic PE slowly develop symptoms of pulmonary hypertension over many years (ie, chronic thromboembolic pulmonary hypertension; CTEPH).</p><p></p><p class="bulletIndent1">An overview of acute and subacute PE is discussed in this review. The etiology, clinical manifestations, diagnosis, and treatment of CTEPH are discussed separately. (See  <a class="medical medical_review" href="/d/html/8254.html" rel="external">"Epidemiology, pathogenesis, clinical manifestations and diagnosis of chronic thromboembolic pulmonary hypertension"</a> and  <a class="medical medical_review" href="/d/html/16637.html" rel="external">"Chronic thromboembolic pulmonary hypertension: Initial management and evaluation for pulmonary artery thromboendarterectomy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>The presence or absence of hemodynamic stability (hemodynamically unstable or stable)</strong> – Hemodynamically unstable PE is also called "<strong>massive</strong>" or "<strong>high-risk</strong>" PE. Hemodynamically stable PE is called "<strong>submassive" </strong>or<strong> </strong>"intermediate-risk" PE if there is associated right ventricular strain, or "low-risk" PE if there is no evidence of right ventricular strain. Hemodynamically stable and unstable PE are defined as the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hemodynamically unstable PE is that which results in hypotension. Hypotension is defined as a systolic blood pressure &lt;90 mmHg or a drop in systolic blood pressure of ≥40 mmHg from baseline for a period &gt;15 minutes or hypotension that requires vasopressors or inotropic support and is not explained by other causes such as sepsis, arrhythmia, left ventricular dysfunction from acute myocardial ischemia or infarction, or hypovolemia. Although hemodynamically unstable PE is often caused by large (ie, massive) PE, it can sometimes be due to small PE in patients with underlying cardiopulmonary disease. Thus, the term "massive" PE does not necessarily describe the size of the PE as much as its hemodynamic effect. (See <a class="local">'Pathophysiologic response to PE'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hemodynamically stable PE is defined as PE that does not meet the definition of hemodynamically unstable PE. There is a spectrum of severity within this population ranging from patients who present with small, mildly symptomatic or asymptomatic PE (also known as "low-risk PE") to those who present with mild or borderline hypotension that stabilizes in response to fluid therapy, or those who present with right ventricle dysfunction (also known as "submassive" or "intermediate-risk" PE). </p><p></p><p class="bulletIndent1">The distinction between hemodynamically stable and unstable PE is important because patients with hemodynamically unstable PE are more likely to die from obstructive shock (ie, severe right ventricular failure). Importantly, death from hemodynamically unstable PE often occurs within the first two hours, and the risk remains elevated for up to 72 hours after presentation [<a href="#rid1">1,2</a>]. (See  <a class="medical medical_review" href="/d/html/8261.html" rel="external">"Clinical presentation, evaluation, and diagnosis of the nonpregnant adult with suspected acute pulmonary embolism", section on 'Hemodynamically unstable patients'</a> and  <a class="medical medical_review" href="/d/html/8265.html" rel="external">"Treatment, prognosis, and follow-up of acute pulmonary embolism in adults", section on 'Prognosis'</a> and  <a class="medical medical_review" href="/d/html/8259.html" rel="external">"Approach to thrombolytic (fibrinolytic) therapy in acute pulmonary embolism: Patient selection and administration", section on 'Hemodynamically unstable patients (high-risk pulmonary embolism)'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>The anatomic location</strong> <strong>(saddle, lobar, segmental, subsegmental)</strong> – Saddle PE lodges at the bifurcation of the main pulmonary artery, often extending into the right and left main pulmonary arteries. Approximately 3 to 6 percent of patients with PE present with a saddle embolus [<a href="#rid3">3,4</a>]. Traditionally, saddle PE was thought to be associated with hemodynamic instability and death. However, retrospective studies suggest that among those diagnosed with a saddle embolus, only 22 percent are hemodynamically unstable, with an associated mortality of 5 percent [<a href="#rid3">3,4</a>]. Clot that is "in transit" through the heart is often classified as a form of PE, even though the thrombus has not yet lodged in a pulmonary artery. Clot-in-transit is associated with high mortality (up to 40 percent). </p><p></p><p class="bulletIndent1">Most PE move beyond the bifurcation of the main pulmonary artery to lodge distally in the main lobar, segmental, or subsegmental branches of a pulmonary artery. PE can be bilateral or unilateral, depending on whether they obstruct arteries in the right, left, or both lungs. Smaller thrombi that are located in the peripheral segmental or subsegmental branches are more likely to cause pulmonary infarction and pleuritis  (<a class="graphic graphic_diagnosticimage graphicRef99736" href="/d/graphic/99736.html" rel="external">image 1</a>). (See <a class="local">'Pathophysiologic response to PE'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>The presence or absence of symptoms (symptomatic or asymptomatic)</strong> – Symptomatic PE refers to the presence of symptoms that usually leads to the radiologic confirmation of PE, whereas asymptomatic PE refers to the incidental finding of PE on imaging (eg, contrast-enhanced computed tomography performed for another reason) in a patient without symptoms. (See  <a class="medical medical_review" href="/d/html/8261.html" rel="external">"Clinical presentation, evaluation, and diagnosis of the nonpregnant adult with suspected acute pulmonary embolism", section on 'Diagnosis'</a>.)</p><p></p><p class="headingAnchor" id="H26146960"><span class="h1">EPIDEMIOLOGY</span></p><p class="headingAnchor" id="H86226299"><span class="h2">General population</span><span class="headingEndMark"> — </span>Estimates of the incidence of pulmonary embolism (PE) in the general population increased following the introduction of D-dimer testing and computed tomographic pulmonary angiography in the 1990s [<a href="#rid5">5-11</a>]. However, studies since then have reported stable rates [<a href="#rid10">10,12</a>]. As an example, reported an incidence rate of PE as 0.38 per 1000 person years, a rate that appeared to be stable between 2002 and 2012 [<a href="#rid10">10</a>]. Another study a reported rate of 2.81 per 100,000 in 2019, which was similar to that in 2006 [<a href="#rid12">12</a>]. </p><p>The overall incidence is higher in males compared with females (56 versus 48 per 100,000, respectively) [<a href="#rid12">12-15</a>]. The incidence rises with increasing age, particularly in women, such that PE has an incidence of &gt;500 per 100,000 after the age of 75 years [<a href="#rid14">14,16</a>]. The use of statins, exercising regularly, and a low body mass index may reduce the incidence of PE [<a href="#rid17">17</a>]. </p><p>In the United States, PE accounts for approximately 100,000 annual deaths [<a href="#rid13">13,18</a>]. In Europe, PE accounts for 300,000 deaths annually [<a href="#rid19">19</a>]. In an analysis based upon data from five European countries, the majority of VTE-related deaths were due to hospital-acquired PE and most were diagnosed antemortem [<a href="#rid20">20</a>]. However, many causes of sudden cardiac death are thought to be secondary to PE, so the actual mortality attributable to PE is difficult to estimate. </p><p>Deaths from diagnosed PE have been declining [<a href="#rid8">8,13,21</a>], with one study reporting deaths from PE that decreased between 1979-1998, from 191 to 94 per million [<a href="#rid13">13</a>]. In another study, the mortality risk ratio from PE declined from 138 (95% CI, 125-153) in 1980-1989 to 36.08 (95% CI, 32.65-39.87) in 2000-2011 [<a href="#rid22">22</a>]. </p><p>Overall mortality from PE appears to be high. Another study reported a 30-day and 1 year mortality at 4 and 13 percent, respectively and a case-fatality rate that increased with increasing age [<a href="#rid10">10</a>]. </p><p>In a review of death certificates in the Multiple-Cause Mortality Files compiled by the National Center for Health Statistics from 1979 to 1998, age-adjusted mortality rates were 50 percent higher in African American compared with White American adults; in turn, mortality rates in White Americans were 50 percent higher compared with other groups (eg, Asian American, American Indian) [<a href="#rid13">13</a>].</p><p class="headingAnchor" id="H86226312"><span class="h2">Special populations</span><span class="headingEndMark"> — </span>The incidence of venous thromboembolism (DVT and PE) in select populations is discussed in the following sections:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with malignancy (see  <a class="medical medical_review" href="/d/html/1352.html" rel="external">"Risk and prevention of venous thromboembolism in adults with cancer", section on 'Incidence and risk factors'</a> and  <a class="medical medical_review" href="/d/html/2505.html" rel="external">"Supportive care for locally advanced or metastatic exocrine pancreatic cancer", section on 'Venous thromboembolism'</a> and  <a class="medical medical_review" href="/d/html/1340.html" rel="external">"Anticoagulation therapy for venous thromboembolism (lower extremity venous thrombosis and pulmonary embolism) in adult patients with malignancy"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients who are pregnant </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with stroke (see  <a class="medical medical_review" href="/d/html/121857.html" rel="external">"Prevention and treatment of venous thromboembolism in patients with acute stroke"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hospitalized medical patients (see  <a class="medical medical_review" href="/d/html/1346.html" rel="external">"Prevention of venous thromboembolic disease in acutely ill hospitalized medical adults", section on 'General medical patients'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hospitalized surgical patients (see  <a class="medical medical_review" href="/d/html/1339.html" rel="external">"Prevention of venous thromboembolic disease in adult nonorthopedic surgical patients"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hospitalized gynecologic patients (see  <a class="medical medical_review" href="/d/html/1352.html" rel="external">"Risk and prevention of venous thromboembolism in adults with cancer", section on 'Incidence and risk factors'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with nephrotic syndrome (see  <a class="medical medical_review" href="/d/html/3043.html" rel="external">"Hypercoagulability in nephrotic syndrome", section on 'Epidemiology'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with acute traumatic spinal cord injury (see  <a class="medical medical_review" href="/d/html/4819.html" rel="external">"Acute traumatic spinal cord injury", section on 'Venous thromboembolism and pulmonary embolism'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with total joint arthroplasty or replacement (see  <a class="medical medical_review" href="/d/html/7971.html" rel="external">"Complications of total knee arthroplasty", section on 'Thromboembolism'</a> and  <a class="medical medical_review" href="/d/html/7973.html" rel="external">"Complications of total hip arthroplasty", section on 'Venous thromboembolism'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with inherited thrombotic disorders (see  <a class="medical medical_review" href="/d/html/1361.html" rel="external">"Overview of the causes of venous thrombosis", section on 'Inherited thrombophilia'</a>)</p><p></p><p class="headingAnchor" id="H12"><span class="h1">PATHOGENESIS AND PATHOPHYSIOLOGY</span></p><p class="headingAnchor" id="H446823322"><span class="h2">Pathogenesis</span><span class="headingEndMark"> — </span>The pathogenesis of pulmonary embolism (PE) is similar to that which underlies the generation of thrombus (ie, Virchow's triad). Virchow's triad consists of venous stasis, endothelial injury, and a hypercoagulable state, which is discussed separately. (See  <a class="medical medical_review" href="/d/html/1361.html" rel="external">"Overview of the causes of venous thrombosis", section on 'Virchow triad'</a>.)</p><p class="headingAnchor" id="H79927589"><span class="h2">Risk factors</span><span class="headingEndMark"> — </span>The few studies that have specifically examined risk factors for PE alone confirm that they are similar to those for venous thromboembolism (VTE) in general [<a href="#rid23">23-29</a>]. Risk factors can be classified as inherited (ie, genetic) and acquired. More than 50 genetic risk factors for VTE have been identified, including factor V Leiden and the prothrombin gene mutation (20210-A) [<a href="#rid30">30-33</a>]. Acquired risk factors can be further sub-classified as provoking (eg, recent surgery, trauma, immobilization, initiation of hormone therapy, active cancer) or non-provoking (eg, obesity, heavy cigarette smoking) [<a href="#rid29">29</a>]. Risk factors for VTE are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/1361.html" rel="external">"Overview of the causes of venous thrombosis"</a>.)  </p><p class="headingAnchor" id="H79927767"><span class="h2">Source</span><span class="headingEndMark"> — </span>Most emboli are thought to arise from lower extremity proximal veins (iliac, femoral, and popliteal)  (<a class="graphic graphic_table graphicRef77469" href="/d/graphic/77469.html" rel="external">table 1</a>) and more than 50 percent of patients with proximal vein deep venous thrombosis (DVT) have concurrent PE at presentation [<a href="#rid34">34-38</a>]. Calf vein DVT rarely embolizes to the lung and two–thirds of calf vein thrombi resolve spontaneously after detection [<a href="#rid39">39-48</a>]. However, if untreated, one-third of calf vein DVT extend into the proximal veins, where they have greater potential to embolize. PE can also arise from DVT in non-lower-extremity veins including renal and upper extremity veins, although embolization from these veins is less common. (See  <a class="medical medical_review" href="/d/html/1362.html" rel="external">"Overview of the treatment of proximal and distal lower extremity deep vein thrombosis (DVT)", section on 'Distal DVT'</a>.) </p><p>Most thrombi develop at sites of decreased flow in the lower extremity veins, such as valve cusps or bifurcations. However, they may also originate in veins with higher venous flow including the inferior vena cava, or the pelvic veins, and in non-lower-extremity veins including renal and upper extremity veins. (See  <a class="medical medical_review" href="/d/html/3043.html" rel="external">"Hypercoagulability in nephrotic syndrome"</a> and  <a class="medical medical_review" href="/d/html/17036.html" rel="external">"Overview of thoracic central venous obstruction"</a>.)</p><p class="headingAnchor" id="H446823334"><span class="h2">Pathophysiologic response to PE</span><span class="headingEndMark"> — </span>Pulmonary emboli are typically multiple, with the lower lobes being involved in the majority of cases [<a href="#rid49">49</a>]. Once thrombus lodges in the lung, a series of pathophysiologic responses can occur:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infarction </strong>– In about 10 percent of patients, small thrombi lodge distally in to the segmental and subsegmental vessels resulting in pulmonary infarction [<a href="#rid50">50</a>]. These patients are more likely to have pleuritic chest pain and hemoptysis, presumed to be due to an intense inflammatory response in the lung and adjacent visceral and parietal pleura.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Abnormal gas exchange</strong> – Impaired gas exchange from PE is due to mechanical and functional obstruction of the vascular bed altering the ventilation to perfusion ratio, and from inflammation resulting in surfactant dysfunction and atelectasis resulting in functional intrapulmonary shunting. Both mechanisms cause hypoxemia [<a href="#rid51">51</a>]. Inflammation is also thought to be responsible for stimulating respiratory drive resulting in hypocapnia and respiratory alkalosis. Hypercapnia and acidosis are unusual in PE unless shock is present. (See  <a class="medical medical_review" href="/d/html/8261.html" rel="external">"Clinical presentation, evaluation, and diagnosis of the nonpregnant adult with suspected acute pulmonary embolism", section on 'Laboratory tests'</a> and  <a class="medical medical_review" href="/d/html/1647.html" rel="external">"Measures of oxygenation and mechanisms of hypoxemia"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cardiovascular compromise</strong> – Hypotension from PE is due to diminished stroke volume and cardiac output. In patients with PE, pulmonary vascular resistance (PVR) is increased due to physical obstruction of the vascular bed with thrombus and hypoxic vasoconstriction within the pulmonary arterial system. Increased PVR, in turn, impedes right ventricular outflow and causes right ventricular dilation and flattening or bowing of the intraventricular septum. Both diminished flow from the right ventricle (RV) and RV dilation reduce left ventricular preload thereby compromising cardiac output.</p><p></p><p class="bulletIndent1">As an example, when obstruction of the pulmonary vascular bed approaches 75 percent, the RV must generate a systolic pressure in excess of 50 mmHg to preserve adequate pulmonary artery flow [<a href="#rid52">52</a>]. When the RV is unable to accomplish this, it fails and hypotension ensues. Thus, in patients without underlying cardiopulmonary disease, multiple large thrombi are generally responsible for hypotension via this mechanism. By contrast, in patients with underlying cardiopulmonary disease, especially those with pre-existing elevations in PVR, hypotension can be induced by smaller emboli, likely due to a substantial vasoconstrictive response and/or an inability of the RV to generate sufficient pressure to combat high PVR. </p><p></p><p class="headingAnchor" id="H13"><span class="h1">CLINICAL PRESENTATION, EVALUATION, AND DIAGNOSIS</span></p><p class="headingAnchor" id="H86227218"><span class="h2">Clinical presentation</span><span class="headingEndMark"> — </span>Pulmonary embolism (PE) has a wide variety of presenting features, ranging from no symptoms to shock or sudden death. The most common presenting symptom is dyspnea followed by chest pain (classically pleuritic in nature, but not always), cough, and symptoms of deep venous thrombosis. Hemoptysis is an unusual presenting symptom. With severe PE, patients can present with shock, arrhythmia, or syncope. Many patients, including some with large PE, are asymptomatic or have mild or nonspecific symptoms. Thus, it is critical that a high level of suspicion be maintained such that clinically relevant cases are not missed. The signs and symptoms of PE are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/8261.html" rel="external">"Clinical presentation, evaluation, and diagnosis of the nonpregnant adult with suspected acute pulmonary embolism", section on 'Clinical presentation'</a>.) </p><p class="headingAnchor" id="H446824308"><span class="h2">Diagnostic approach to patients with suspected PE</span><span class="headingEndMark"> — </span>For most patients with suspected PE who are hemodynamically stable, we suggest an approach which combines clinical and pretest probability assessment (<a class="calc calc_professional" href="/d/html/13446.html" rel="external">calculator 1</a>)  (<a class="graphic graphic_table graphicRef54767" href="/d/graphic/54767.html" rel="external">table 2</a>), D-dimer testing, and definitive diagnostic imaging  (<a class="graphic graphic_algorithm graphicRef113963" href="/d/graphic/113963.html" rel="external">algorithm 1</a> and <a class="graphic graphic_algorithm graphicRef113962" href="/d/graphic/113962.html" rel="external">algorithm 2</a> and <a class="graphic graphic_algorithm graphicRef113961" href="/d/graphic/113961.html" rel="external">algorithm 3</a>). Definitive imaging includes computed tomographic pulmonary angiography and less commonly, ventilation perfusion scanning or other imaging modalities. For patients who are hemodynamically unstable and in whom definitive imaging is unsafe, bedside echocardiography or venous compression ultrasound may be used to obtain a presumptive diagnosis of PE to justify the administration of potentially life-saving therapies.</p><p>Details regarding the evaluation and diagnostic approach to patients with suspected PE are discussed separately. (See  <a class="medical medical_review" href="/d/html/8261.html" rel="external">"Clinical presentation, evaluation, and diagnosis of the nonpregnant adult with suspected acute pulmonary embolism"</a>.) <span class="utd-adt-cnt utd-adt-pathwys utd-content-120066 utd-content-120062">(Related Pathway(s):  <a class="utd-content-120066" href="/pathway/120066?topicRef=8253&amp;source=see_link">Pulmonary embolism: Diagnostic evaluation in adults who are hemodynamically stable</a> and  <a class="utd-content-120062" href="/pathway/120062?topicRef=8253&amp;source=see_link">Pulmonary embolism: Diagnostic evaluation in adults who are hemodynamically unstable despite resuscitative efforts</a>.)</span></p><p class="headingAnchor" id="H15"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>When a patient presents with suspected acute pulmonary embolism (PE), initial resuscitative therapy should focus upon oxygenating and stabilizing the patient. Resuscitative therapy may range from supplemental oxygen to ventilatory and hemodynamic support. Intravenous fluid resuscitation should be limited, as further distention of an already dilated right ventricle (RV) can worsen hemodynamics. If possible, endotracheal intubation should be avoided, as positive pressure ventilation can reduce preload and compress the failing RV, leading to hemodynamic collapse. An overview of the general measures used to resuscitate patients with suspected PE is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/8265.html" rel="external">"Treatment, prognosis, and follow-up of acute pulmonary embolism in adults"</a>.) </p><p>Once the diagnosis is made, the mainstay of therapy for patients with confirmed PE is anticoagulation, depending upon the risk of bleeding. When the pre-test probability of PE is high or diagnostic imaging will be delayed, anticoagulation is sometimes started before a diagnosis of PE is confirmed. Data that support initial, long-term, and indefinite anticoagulation, and factors that determine whether or not a patient can be treated in the outpatient setting (ie, without hospitalization), are discussed separately. (See  <a class="medical medical_review" href="/d/html/94740.html" rel="external">"Selecting adult patients with lower extremity deep venous thrombosis and pulmonary embolism for indefinite anticoagulation"</a> and  <a class="medical medical_review" href="/d/html/8265.html" rel="external">"Treatment, prognosis, and follow-up of acute pulmonary embolism in adults", section on 'Outpatient anticoagulation'</a> and  <a class="medical medical_review" href="/d/html/95336.html" rel="external">"Venous thromboembolism: Initiation of anticoagulation"</a>.) <span class="utd-adt-cnt utd-adt-pathwys utd-content-120060 utd-content-120061">(Related Pathway(s):  <a class="utd-content-120060" href="/pathway/120060?topicRef=8253&amp;source=see_link">Pulmonary embolism (confirmed or suspected): Initial management of hemodynamically stable adults</a> and  <a class="utd-content-120061" href="/pathway/120061?topicRef=8253&amp;source=see_link">Pulmonary embolism (confirmed or suspected): Initial management of hemodynamically unstable adults</a>.)</span></p><p>Patients with life-threatening PE may require additional treatment beyond anticoagulation, including thrombolysis, inferior vena cava filters, and embolectomy. Select populations that require specific anticoagulation or alternative treatment strategies include:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with malignancy (see  <a class="medical medical_review" href="/d/html/1340.html" rel="external">"Anticoagulation therapy for venous thromboembolism (lower extremity venous thrombosis and pulmonary embolism) in adult patients with malignancy"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients who are pregnant (see  <a class="medical medical_review" href="/d/html/1350.html" rel="external">"Venous thromboembolism in pregnancy and postpartum: Treatment"</a> and  <a class="medical medical_review" href="/d/html/1342.html" rel="external">"Use of anticoagulants during pregnancy and postpartum"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with heparin-induced thrombocytopenia (see  <a class="medical medical_review" href="/d/html/90261.html" rel="external">"Clinical presentation and diagnosis of heparin-induced thrombocytopenia"</a> and  <a class="medical medical_review" href="/d/html/1369.html" rel="external">"Management of heparin-induced thrombocytopenia"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with a contraindication to anticoagulation (inferior vena cava filter placement) (see  <a class="medical medical_review" href="/d/html/8212.html" rel="external">"Placement of vena cava filters and their complications"</a> and  <a class="medical medical_review" href="/d/html/1362.html" rel="external">"Overview of the treatment of proximal and distal lower extremity deep vein thrombosis (DVT)", section on 'Inferior vena cava filter'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients who are hemodynamically unstable or fail anticoagulation (thrombolytic therapy and/or embolectomy) (see  <a class="medical medical_review" href="/d/html/8259.html" rel="external">"Approach to thrombolytic (fibrinolytic) therapy in acute pulmonary embolism: Patient selection and administration"</a> and  <a class="medical medical_review" href="/d/html/8265.html" rel="external">"Treatment, prognosis, and follow-up of acute pulmonary embolism in adults", section on 'Embolectomy'</a>)</p><p></p><p class="headingAnchor" id="H86226720"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>The major adverse outcomes associated with pulmonary embolism (PE) include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Recurrent thromboembolism – The recurrence rate depends upon factors including adequate therapeutic anticoagulation and the clinical nature of the embolic event (eg, provoked, unprovoked), the details of which are discussed separately. (See  <a class="medical medical_review" href="/d/html/94740.html" rel="external">"Selecting adult patients with lower extremity deep venous thrombosis and pulmonary embolism for indefinite anticoagulation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Chronic thromboembolic pulmonary hypertension (CTEPH) – CTEPH is an uncommon (1 to 4 percent) late outcome of patients with PE. The prognosis of patients with CTEPH is discussed separately. (See  <a class="medical medical_review" href="/d/html/16637.html" rel="external">"Chronic thromboembolic pulmonary hypertension: Initial management and evaluation for pulmonary artery thromboendarterectomy"</a>.)  </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Death – PE left untreated is associated with an overall mortality of up to 30 percent. Mortality is significantly reduced with anticoagulation. Most deaths attributable to PE occur during the first week following diagnosis (early mortality) and are due to shock and recurrent venous thromboembolism. However, many deaths following PE are due to predisposing comorbidities or are multifactorial. One study demonstrated increased risk of death for up to eight years in patients without comorbidities [<a href="#rid53">53</a>], while other studies have reported that mortality remains increased for as long as 30 years (long-term mortality) with death mostly due to predisposing comorbidities (eg, cardiovascular disease, malignancy, sepsis) [<a href="#rid22">22</a>]. Details regarding the mortality of patients diagnosed with PE are discussed separately. (See  <a class="medical medical_review" href="/d/html/8265.html" rel="external">"Treatment, prognosis, and follow-up of acute pulmonary embolism in adults", section on 'Morbidity and mortality'</a>.)</p><p></p><p>Prognostic models that incorporate clinical findings with or without laboratory tests can predict death and/or recurrence. Among prognostic models, the Pulmonary Embolism Severity Index (PESI), the simplified PESI (sPESI), and the Hestia Criteria [<a href="#rid54">54</a>] are the most well known  (<a class="graphic graphic_table graphicRef90549" href="/d/graphic/90549.html" rel="external">table 3</a>) and predict all-cause mortality after PE. A detailed discussion of the prognostic value of these and other models is presented separately. (See  <a class="medical medical_review" href="/d/html/8265.html" rel="external">"Treatment, prognosis, and follow-up of acute pulmonary embolism in adults", section on 'Prognostic factors'</a> and  <a class="medical medical_review" href="/d/html/8265.html" rel="external">"Treatment, prognosis, and follow-up of acute pulmonary embolism in adults", section on 'Prognostic models'</a>.)</p><p class="headingAnchor" id="H86227129"><span class="h1">MONITORING AND FOLLOW-UP</span><span class="headingEndMark"> — </span>Patients with pulmonary embolism (PE) should be monitored for the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Laboratory evidence of therapeutic efficacy in patients receiving <a class="drug drug_general" data-topicid="8518" href="/d/drug information/8518.html" rel="external">unfractionated heparin</a> and/or <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a>. (See  <a class="medical medical_review" href="/d/html/1334.html" rel="external">"Warfarin and other VKAs: Dosing and adverse effects", section on 'Warfarin administration'</a> and  <a class="medical medical_review" href="/d/html/1370.html" rel="external">"Direct oral anticoagulants (DOACs) and parenteral direct-acting anticoagulants: Dosing and adverse effects"</a> and  <a class="medical medical_review" href="/d/html/1348.html" rel="external">"Heparin and LMW heparin: Dosing and adverse effects", section on 'Laboratory monitoring and dose titration (unfractionated heparin)'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Early complications of PE, predominantly recurrent thromboembolism and progression of the diagnosed PE. (See  <a class="medical medical_review" href="/d/html/8261.html" rel="external">"Clinical presentation, evaluation, and diagnosis of the nonpregnant adult with suspected acute pulmonary embolism", section on 'Clinical presentation'</a>.) Patients with confirmed recurrent PE while on therapy should be evaluated for sub-therapeutic anticoagulation or, if anticoagulation is adequate, other causes of recurrence. Investigating and managing the early complications of PE, including recurrence, are discussed separately. (See  <a class="medical medical_review" href="/d/html/8265.html" rel="external">"Treatment, prognosis, and follow-up of acute pulmonary embolism in adults", section on 'Monitoring and follow-up'</a> and  <a class="medical medical_review" href="/d/html/8265.html" rel="external">"Treatment, prognosis, and follow-up of acute pulmonary embolism in adults", section on 'Management of recurrence on therapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Late complications of PE, mostly, chronic thromboembolic pulmonary hypertension CTEPH. Most patients who develop CTEPH do so in the first two years following PE and the diagnosis is usually suspected clinically because of persistent symptoms. The clinical presentation and diagnosis of CTEPH are discussed separately. (See  <a class="medical medical_review" href="/d/html/8254.html" rel="external">"Epidemiology, pathogenesis, clinical manifestations and diagnosis of chronic thromboembolic pulmonary hypertension"</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Complications of therapy for PE, including bleeding and adverse effects of medication or devices. (See  <a class="medical medical_review" href="/d/html/1334.html" rel="external">"Warfarin and other VKAs: Dosing and adverse effects", section on 'Complications'</a> and  <a class="medical medical_review" href="/d/html/1370.html" rel="external">"Direct oral anticoagulants (DOACs) and parenteral direct-acting anticoagulants: Dosing and adverse effects"</a> and  <a class="medical medical_review" href="/d/html/8212.html" rel="external">"Placement of vena cava filters and their complications", section on 'Complications'</a> and  <a class="medical medical_review" href="/d/html/8265.html" rel="external">"Treatment, prognosis, and follow-up of acute pulmonary embolism in adults", section on 'Embolectomy'</a> and  <a class="medical medical_review" href="/d/html/1348.html" rel="external">"Heparin and LMW heparin: Dosing and adverse effects", section on 'Other complications'</a> and  <a class="medical medical_review" href="/d/html/1324.html" rel="external">"Management of warfarin-associated bleeding or supratherapeutic INR", section on 'Mitigating bleeding risk'</a> and  <a class="medical medical_review" href="/d/html/119889.html" rel="external">"Risks and prevention of bleeding with oral anticoagulants"</a> and  <a class="medical medical_review" href="/d/html/8259.html" rel="external">"Approach to thrombolytic (fibrinolytic) therapy in acute pulmonary embolism: Patient selection and administration", section on 'Efficacy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The risk of recurrence and bleeding. The risk of recurrence and bleeding should be periodically assessed during therapy and, again, at the end of therapy to assess the need for indefinite anticoagulation. Assessing recurrence and bleeding risk as well as indications for indefinite anticoagulation are discussed separately. (See  <a class="medical medical_review" href="/d/html/94740.html" rel="external">"Selecting adult patients with lower extremity deep venous thrombosis and pulmonary embolism for indefinite anticoagulation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The need for device removal. Patients who had an inferior vena cava filter placed because anticoagulation was contraindicated should, once the contraindication has resolved, initiate anticoagulant therapy and have the filter retrieved, if feasible. (See  <a class="medical medical_review" href="/d/html/8212.html" rel="external">"Placement of vena cava filters and their complications", section on 'Filter retrieval'</a>.) </p><p></p><p class="headingAnchor" id="H3242820754"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/113663.html" rel="external">"Society guideline links: Superficial vein thrombosis, deep vein thrombosis, and pulmonary embolism"</a>.)</p><p class="headingAnchor" id="H17"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/16922.html" rel="external">"Patient education: Pulmonary embolism (blood clot in the lung) (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/696.html" rel="external">"Patient education: Pulmonary embolism (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H18"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition and nomenclature</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Pulmonary embolism (PE) is a common and sometimes fatal disease. It is due to obstruction of a pulmonary artery or one of its branches by material (eg, thrombus, tumor, air, or fat) that originated elsewhere in the body. (See <a class="local">'Definition'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>PE can be classified according to the following (see <a class="local">'Nomenclature'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>The presence or absence of hemodynamic stability (hemodynamically unstable or stable)</p><p class="bulletIndent3"><span class="glyph">-</span>The temporal pattern of presentation (acute, subacute, or chronic),</p><p class="bulletIndent3"><span class="glyph">-</span>The anatomic location (saddle, lobar, segmental, subsegmental)</p><p class="bulletIndent3"><span class="glyph">-</span>The presence or absence of symptoms (symptomatic or asymptomatic). </p><p></p><p class="bulletIndent2">Patients with hemodynamically unstable PE, defined as a systolic blood pressure &lt;90 mmHg or a drop in systolic blood pressure of ≥40 mmHg from baseline for &gt;15 minutes, should be distinguished from patients with hemodynamically stable PE because they are more likely to die from obstructive shock in the first two hours of presentation and may therefore benefit from more aggressive treatment. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology</strong> – The overall incidence of PE is approximately 112 cases per 100,000. PE is slightly more common in males than females and incidence increases with age. Deaths from PE account for approximately 100,000 deaths per year in the United States. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis</strong> – The pathogenesis of PE is similar to that of deep venous thrombosis. Most emboli arise from lower extremity proximal veins (iliac, femoral, and popliteal)  (<a class="graphic graphic_table graphicRef77469" href="/d/graphic/77469.html" rel="external">table 1</a>). However, they may also originate in right heart, inferior vena cava or the pelvic veins, and in the renal and upper extremity veins. (See  <a class="medical medical_review" href="/d/html/1361.html" rel="external">"Overview of the causes of venous thrombosis"</a> and <a class="local">'Pathogenesis and pathophysiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Presentation and diagnosis</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Presentation – PE has a wide variety of presenting features, ranging from no symptoms to shock or sudden death. The most common presenting symptom is dyspnea followed by chest pain, cough, and symptoms of deep venous thrombosis. Further details are provided separately. (See  <a class="medical medical_review" href="/d/html/8261.html" rel="external">"Clinical presentation, evaluation, and diagnosis of the nonpregnant adult with suspected acute pulmonary embolism"</a> and <a class="local">'Clinical presentation, evaluation, and diagnosis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph utd-adt-cnt utd-adt-pathwys">•</span>Diagnosis – For most patients with suspected PE we suggest an approach which combines clinical and pretest probability assessment (<a class="calc calc_professional" href="/d/html/13446.html" rel="external">calculator 1</a>)  (<a class="graphic graphic_table graphicRef54767" href="/d/graphic/54767.html" rel="external">table 2</a>), D-dimer testing, and definitive diagnostic imaging, usually computed tomographic pulmonary angiography and, less commonly, ventilation perfusion scanning  (<a class="graphic graphic_algorithm graphicRef113963" href="/d/graphic/113963.html" rel="external">algorithm 1</a> and <a class="graphic graphic_algorithm graphicRef113962" href="/d/graphic/113962.html" rel="external">algorithm 2</a> and <a class="graphic graphic_algorithm graphicRef113961" href="/d/graphic/113961.html" rel="external">algorithm 3</a>). Further details are provided separately. (See  <a class="medical medical_review" href="/d/html/8261.html" rel="external">"Clinical presentation, evaluation, and diagnosis of the nonpregnant adult with suspected acute pulmonary embolism"</a> and <a class="local">'Diagnostic approach to patients with suspected PE'</a> above.) <span class="utd-adt-cnt utd-adt-pathwys utd-content-120066 utd-content-120062">(Related Pathway(s):  <a class="utd-content-120066" href="/pathway/120066?topicRef=8253&amp;source=see_link">Pulmonary embolism: Diagnostic evaluation in adults who are hemodynamically stable</a> and  <a class="utd-content-120062" href="/pathway/120062?topicRef=8253&amp;source=see_link">Pulmonary embolism: Diagnostic evaluation in adults who are hemodynamically unstable despite resuscitative efforts</a>.)</span></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment and prognosis </strong></p><p></p><p class="bulletIndent2"><span class="glyph utd-adt-cnt utd-adt-pathwys">•</span>Initial resuscitative therapy for patients with suspected PE should focus upon oxygenating and stabilizing the patient. Once the diagnosis is made, the mainstay of therapy for patients with confirmed PE is anticoagulation, depending upon the risk of bleeding. Alternative treatments include thrombolysis, inferior vena cava filters, and embolectomy. Further details are provided separately. (See  <a class="medical medical_review" href="/d/html/8265.html" rel="external">"Treatment, prognosis, and follow-up of acute pulmonary embolism in adults"</a> and <a class="local">'Treatment'</a> above.) <span class="utd-adt-cnt utd-adt-pathwys utd-content-120060 utd-content-120061">(Related Pathway(s):  <a class="utd-content-120060" href="/pathway/120060?topicRef=8253&amp;source=see_link">Pulmonary embolism (confirmed or suspected): Initial management of hemodynamically stable adults</a> and  <a class="utd-content-120061" href="/pathway/120061?topicRef=8253&amp;source=see_link">Pulmonary embolism (confirmed or suspected): Initial management of hemodynamically unstable adults</a>.)</span></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>PE can be complicated by recurrent thrombosis, chronic thromboembolic pulmonary hypertension (CTEPH), and death. PE left untreated, has an overall mortality of up to 30 percent, which is significantly reduced with anticoagulation. Prognostic models that incorporate clinical findings (eg, Pulmonary Embolism Severity Index [PESI] and the simplified PESI [sPESI]  (<a class="graphic graphic_table graphicRef90549" href="/d/graphic/90549.html" rel="external">table 3</a>) and the Hestia Criteria) with or without laboratory tests can predict death and/or recurrence. Further details are provided separately. (See  <a class="medical medical_review" href="/d/html/8265.html" rel="external">"Treatment, prognosis, and follow-up of acute pulmonary embolism in adults", section on 'Prognosis'</a> and <a class="local">'Prognosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Follow-up</strong> – Patients treated with <a class="drug drug_general" data-topicid="8518" href="/d/drug information/8518.html" rel="external">unfractionated heparin</a> and/or <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> should be monitored for laboratory evidence of therapeutic efficacy. In addition, patients should be monitored for the early and late complications of PE, as well as for the complications of anticoagulation and other definitive therapies. (See  <a class="medical medical_review" href="/d/html/8265.html" rel="external">"Treatment, prognosis, and follow-up of acute pulmonary embolism in adults", section on 'Monitoring and follow-up'</a> and  <a class="medical medical_review" href="/d/html/8265.html" rel="external">"Treatment, prognosis, and follow-up of acute pulmonary embolism in adults", section on 'Management of recurrence on therapy'</a> and <a class="local">'Monitoring and follow-up'</a> above.)</p><p></p><p class="headingAnchor" id="H1341504703"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Charles Hales, MD, now deceased, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">COON WW, WILLIS PW. Deep venous thrombosis and pulmonary embolism: prediction, prevention and treatment. Am J Cardiol 1959; 4:611.</a></li><li><a class="nounderline abstract_t">Soloff LA, Rodman T. Acute pulmonary embolism. II. Clinical. Am Heart J 1967; 74:829.</a></li><li><a class="nounderline abstract_t">Ryu JH, Pellikka PA, Froehling DA, et al. Saddle pulmonary embolism diagnosed by CT angiography: frequency, clinical features and outcome. Respir Med 2007; 101:1537.</a></li><li><a class="nounderline abstract_t">Sardi A, Gluskin J, Guttentag A, et al. Saddle pulmonary embolism: is it as bad as it looks? A community hospital experience. Crit Care Med 2011; 39:2413.</a></li><li><a class="nounderline abstract_t">Wiener RS, Schwartz LM, Woloshin S. Time trends in pulmonary embolism in the United States: evidence of overdiagnosis. Arch Intern Med 2011; 171:831.</a></li><li><a class="nounderline abstract_t">Kröger K, Küpper-Nybelen J, Moerchel C, et al. Prevalence and economic burden of pulmonary embolism in Germany. Vasc Med 2012; 17:303.</a></li><li><a class="nounderline abstract_t">Huang W, Goldberg RJ, Anderson FA, et al. Secular trends in occurrence of acute venous thromboembolism: the Worcester VTE study (1985-2009). Am J Med 2014; 127:829.</a></li><li><a class="nounderline abstract_t">Goldacre MJ, Roberts S, Yeates D, Griffith M. Hospital admission and mortality rates for venous thromboembolism in Oxford region, UK, 1975-98. Lancet 2000; 355:1968.</a></li><li><a class="nounderline abstract_t">Martinez C, Cohen AT, Bamber L, Rietbrock S. Epidemiology of first and recurrent venous thromboembolism: a population-based cohort study in patients without active cancer. Thromb Haemost 2014; 112:255.</a></li><li><a class="nounderline abstract_t">Alotaibi GS, Wu C, Senthilselvan A, McMurtry MS. Secular Trends in Incidence and Mortality of Acute Venous Thromboembolism: The AB-VTE Population-Based Study. Am J Med 2016; 129:879.e19.</a></li><li><a class="nounderline abstract_t">Konstantinides SV. Trends in incidence versus case fatality rates of pulmonary embolism: Good news or bad news? Thromb Haemost 2016; 115:233.</a></li><li><a class="nounderline abstract_t">Zghouzi M, Mwansa H, Shore S, et al. Sex, Racial, and Geographic Disparities in Pulmonary Embolism-related Mortality Nationwide. Ann Am Thorac Soc 2023; 20:1571.</a></li><li><a class="nounderline abstract_t">Horlander KT, Mannino DM, Leeper KV. Pulmonary embolism mortality in the United States, 1979-1998: an analysis using multiple-cause mortality data. Arch Intern Med 2003; 163:1711.</a></li><li><a class="nounderline abstract_t">Silverstein MD, Heit JA, Mohr DN, et al. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 1998; 158:585.</a></li><li><a class="nounderline abstract_t">Naess IA, Christiansen SC, Romundstad P, et al. Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost 2007; 5:692.</a></li><li><a class="nounderline abstract_t">Tagalakis V, Patenaude V, Kahn SR, Suissa S. Incidence of and mortality from venous thromboembolism in a real-world population: the Q-VTE Study Cohort. Am J Med 2013; 126:832.e13.</a></li><li><a class="nounderline abstract_t">Lassila R, Jula A, Pitkäniemi J, Haukka J. The association of statin use with reduced incidence of venous thromboembolism: a population-based cohort study. BMJ Open 2014; 4:e005862.</a></li><li class="breakAll">The Surgeon General's call to action to prevent deep vein thrombosis and pulmonary embolism. United States Department of Health and Human Services, 2008.</li><li class="breakAll">Arya R. Venous thromboembolim prevention. London: Department of Health, 2009.</li><li><a class="nounderline abstract_t">Cohen AT, Agnelli G, Anderson FA, et al. Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost 2007; 98:756.</a></li><li><a class="nounderline abstract_t">Smith SB, Geske JB, Kathuria P, et al. Analysis of National Trends in Admissions for Pulmonary Embolism. Chest 2016; 150:35.</a></li><li><a class="nounderline abstract_t">Søgaard KK, Schmidt M, Pedersen L, et al. 30-year mortality after venous thromboembolism: a population-based cohort study. Circulation 2014; 130:829.</a></li><li><a class="nounderline abstract_t">Stein PD, Beemath A, Matta F, et al. Clinical characteristics of patients with acute pulmonary embolism: data from PIOPED II. Am J Med 2007; 120:871.</a></li><li><a class="nounderline abstract_t">PIOPED Investigators. Value of the ventilation/perfusion scan in acute pulmonary embolism. Results of the prospective investigation of pulmonary embolism diagnosis (PIOPED). JAMA 1990; 263:2753.</a></li><li><a class="nounderline abstract_t">Darze ES, Latado AL, Guimarães AG, et al. Incidence and clinical predictors of pulmonary embolism in severe heart failure patients admitted to a coronary care unit. Chest 2005; 128:2576.</a></li><li><a class="nounderline abstract_t">Heit JA, O'Fallon WM, Petterson TM, et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med 2002; 162:1245.</a></li><li><a class="nounderline abstract_t">Pulido T, Aranda A, Zevallos MA, et al. Pulmonary embolism as a cause of death in patients with heart disease: an autopsy study. Chest 2006; 129:1282.</a></li><li><a class="nounderline abstract_t">Zöller B, Li X, Sundquist J, Sundquist K. Risk of pulmonary embolism in patients with autoimmune disorders: a nationwide follow-up study from Sweden. Lancet 2012; 379:244.</a></li><li><a class="nounderline abstract_t">Goldhaber SZ, Grodstein F, Stampfer MJ, et al. A prospective study of risk factors for pulmonary embolism in women. JAMA 1997; 277:642.</a></li><li><a class="nounderline abstract_t">Gohil R, Peck G, Sharma P. The genetics of venous thromboembolism. A meta-analysis involving approximately 120,000 cases and 180,000 controls. Thromb Haemost 2009; 102:360.</a></li><li><a class="nounderline abstract_t">Germain M, Chasman DI, de Haan H, et al. Meta-analysis of 65,734 individuals identifies TSPAN15 and SLC44A2 as two susceptibility loci for venous thromboembolism. Am J Hum Genet 2015; 96:532.</a></li><li><a class="nounderline abstract_t">Klarin D, Busenkell E, Judy R, et al. Genome-wide association analysis of venous thromboembolism identifies new risk loci and genetic overlap with arterial vascular disease. Nat Genet 2019; 51:1574.</a></li><li><a class="nounderline abstract_t">Lindström S, Wang L, Smith EN, et al. Genomic and transcriptomic association studies identify 16 novel susceptibility loci for venous thromboembolism. Blood 2019; 134:1645.</a></li><li><a class="nounderline abstract_t">Girard P, Decousus M, Laporte S, et al. Diagnosis of pulmonary embolism in patients with proximal deep vein thrombosis: specificity of symptoms and perfusion defects at baseline and during anticoagulant therapy. Am J Respir Crit Care Med 2001; 164:1033.</a></li><li><a class="nounderline abstract_t">Kistner RL, Ball JJ, Nordyke RA, Freeman GC. Incidence of pulmonary embolism in the course of thrombophlebitis of the lower extremities. Am J Surg 1972; 124:169.</a></li><li><a class="nounderline abstract_t">Moser KM, LeMoine JR. Is embolic risk conditioned by location of deep venous thrombosis? Ann Intern Med 1981; 94:439.</a></li><li><a class="nounderline abstract_t">Weinmann EE, Salzman EW. Deep-vein thrombosis. N Engl J Med 1994; 331:1630.</a></li><li><a class="nounderline abstract_t">van Langevelde K, Srámek A, Vincken PW, et al. Finding the origin of pulmonary emboli with a total-body magnetic resonance direct thrombus imaging technique. Haematologica 2013; 98:309.</a></li><li><a class="nounderline abstract_t">Kearon C. Natural history of venous thromboembolism. Circulation 2003; 107:I22.</a></li><li><a class="nounderline abstract_t">Masuda EM, Kistner RL. The case for managing calf vein thrombi with duplex surveillance and selective anticoagulation. Dis Mon 2010; 56:601.</a></li><li><a class="nounderline abstract_t">Righini M, Paris S, Le Gal G, et al. Clinical relevance of distal deep vein thrombosis. Review of literature data. Thromb Haemost 2006; 95:56.</a></li><li><a class="nounderline abstract_t">Schwarz T, Schmidt B, Beyer J, Schellong SM. Therapy of isolated calf muscle vein thrombosis with low-molecular-weight heparin. Blood Coagul Fibrinolysis 2001; 12:597.</a></li><li><a class="nounderline abstract_t">Macdonald PS, Kahn SR, Miller N, Obrand D. Short-term natural history of isolated gastrocnemius and soleal vein thrombosis. J Vasc Surg 2003; 37:523.</a></li><li><a class="nounderline abstract_t">Gillet JL, Perrin MR, Allaert FA. Short-term and mid-term outcome of isolated symptomatic muscular calf vein thrombosis. J Vasc Surg 2007; 46:513.</a></li><li><a class="nounderline abstract_t">Lautz TB, Abbas F, Walsh SJ, et al. Isolated gastrocnemius and soleal vein thrombosis: should these patients receive therapeutic anticoagulation? Ann Surg 2010; 251:735.</a></li><li><a class="nounderline abstract_t">Schwarz T, Buschmann L, Beyer J, et al. Therapy of isolated calf muscle vein thrombosis: a randomized, controlled study. J Vasc Surg 2010; 52:1246.</a></li><li><a class="nounderline abstract_t">Sales CM, Haq F, Bustami R, Sun F. Management of isolated soleal and gastrocnemius vein thrombosis. J Vasc Surg 2010; 52:1251.</a></li><li><a class="nounderline abstract_t">Palareti G, Cosmi B, Lessiani G, et al. Evolution of untreated calf deep-vein thrombosis in high risk symptomatic outpatients: the blind, prospective CALTHRO study. Thromb Haemost 2010; 104:1063.</a></li><li><a class="nounderline abstract_t">Moser KM. Venous thromboembolism. Am Rev Respir Dis 1990; 141:235.</a></li><li><a class="nounderline abstract_t">Stein PD, Terrin ML, Hales CA, et al. Clinical, laboratory, roentgenographic, and electrocardiographic findings in patients with acute pulmonary embolism and no pre-existing cardiac or pulmonary disease. Chest 1991; 100:598.</a></li><li><a class="nounderline abstract_t">Nakos G, Kitsiouli EI, Lekka ME. Bronchoalveolar lavage alterations in pulmonary embolism. Am J Respir Crit Care Med 1998; 158:1504.</a></li><li><a class="nounderline abstract_t">Benotti JR, Dalen JE. The natural history of pulmonary embolism. Clin Chest Med 1984; 5:403.</a></li><li><a class="nounderline abstract_t">Flinterman LE, van Hylckama Vlieg A, Cannegieter SC, Rosendaal FR. Long-term survival in a large cohort of patients with venous thrombosis: incidence and predictors. PLoS Med 2012; 9:e1001155.</a></li><li><a class="nounderline abstract_t">Zondag W, Mos IC, Creemers-Schild D, et al. Outpatient treatment in patients with acute pulmonary embolism: the Hestia Study. J Thromb Haemost 2011; 9:1500.</a></li></ol></div><div id="topicVersionRevision">Topic 8253 Version 52.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13811755" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Deep venous thrombosis and pulmonary embolism: prediction, prevention and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6073360" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Acute pulmonary embolism. II. Clinical.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17254761" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Saddle pulmonary embolism diagnosed by CT angiography: frequency, clinical features and outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21705903" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Saddle pulmonary embolism: is it as bad as it looks? A community hospital experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21555660" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Time trends in pulmonary embolism in the United States: evidence of overdiagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22751745" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Prevalence and economic burden of pulmonary embolism in Germany.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24813864" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Secular trends in occurrence of acute venous thromboembolism: the Worcester VTE study (1985-2009).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10859045" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Hospital admission and mortality rates for venous thromboembolism in Oxford region, UK, 1975-98.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24695909" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Epidemiology of first and recurrent venous thromboembolism: a population-based cohort study in patients without active cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26925811" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Secular Trends in Incidence and Mortality of Acute Venous Thromboembolism: The AB-VTE Population-Based Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26632213" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Trends in incidence versus case fatality rates of pulmonary embolism: Good news or bad news?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37555732" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Sex, Racial, and Geographic Disparities in Pulmonary Embolism-related Mortality Nationwide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12885687" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Pulmonary embolism mortality in the United States, 1979-1998: an analysis using multiple-cause mortality data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9521222" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17367492" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Incidence and mortality of venous thrombosis: a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23830539" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Incidence of and mortality from venous thromboembolism in a real-world population: the Q-VTE Study Cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25377011" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : The association of statin use with reduced incidence of venous thromboembolism: a population-based cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25377011" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : The association of statin use with reduced incidence of venous thromboembolism: a population-based cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25377011" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : The association of statin use with reduced incidence of venous thromboembolism: a population-based cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17938798" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26905364" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Analysis of National Trends in Admissions for Pulmonary Embolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24970783" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : 30-year mortality after venous thromboembolism: a population-based cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17904458" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Clinical characteristics of patients with acute pulmonary embolism: data from PIOPED II.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2332918" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Value of the ventilation/perfusion scan in acute pulmonary embolism. Results of the prospective investigation of pulmonary embolism diagnosis (PIOPED).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16236926" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Incidence and clinical predictors of pulmonary embolism in severe heart failure patients admitted to a coronary care unit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12038942" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16685020" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Pulmonary embolism as a cause of death in patients with heart disease: an autopsy study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22119579" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Risk of pulmonary embolism in patients with autoimmune disorders: a nationwide follow-up study from Sweden.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9039882" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : A prospective study of risk factors for pulmonary embolism in women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19652888" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : The genetics of venous thromboembolism. A meta-analysis involving approximately 120,000 cases and 180,000 controls.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25772935" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Meta-analysis of 65,734 individuals identifies TSPAN15 and SLC44A2 as two susceptibility loci for venous thromboembolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31676865" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Genome-wide association analysis of venous thromboembolism identifies new risk loci and genetic overlap with arterial vascular disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31420334" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Genomic and transcriptomic association studies identify 16 novel susceptibility loci for venous thromboembolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11587992" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Diagnosis of pulmonary embolism in patients with proximal deep vein thrombosis: specificity of symptoms and perfusion defects at baseline and during anticoagulant therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5045886" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Incidence of pulmonary embolism in the course of thrombophlebitis of the lower extremities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7212500" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Is embolic risk conditioned by location of deep venous thrombosis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7772110" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Deep-vein thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22801962" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Finding the origin of pulmonary emboli with a total-body magnetic resonance direct thrombus imaging technique.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12814982" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Natural history of venous thromboembolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20971331" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : The case for managing calf vein thrombi with duplex surveillance and selective anticoagulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16543962" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Clinical relevance of distal deep vein thrombosis. Review of literature data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11685050" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Therapy of isolated calf muscle vein thrombosis with low-molecular-weight heparin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12618686" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Short-term natural history of isolated gastrocnemius and soleal vein thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17681715" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Short-term and mid-term outcome of isolated symptomatic muscular calf vein thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19858700" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Isolated gastrocnemius and soleal vein thrombosis: should these patients receive therapeutic anticoagulation?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20630682" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Therapy of isolated calf muscle vein thrombosis: a randomized, controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20630686" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Management of isolated soleal and gastrocnemius vein thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20694281" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Evolution of untreated calf deep-vein thrombosis in high risk symptomatic outpatients: the blind, prospective CALTHRO study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2404439" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Venous thromboembolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1909617" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Clinical, laboratory, roentgenographic, and electrocardiographic findings in patients with acute pulmonary embolism and no pre-existing cardiac or pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9817700" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Bronchoalveolar lavage alterations in pulmonary embolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6488744" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : The natural history of pulmonary embolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22253578" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Long-term survival in a large cohort of patients with venous thrombosis: incidence and predictors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21645235" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Outpatient treatment in patients with acute pulmonary embolism: the Hestia Study.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
